Oddo BHF Asset Management Sas Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Oddo BHF Asset Management Sas increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,013 shares of the biopharmaceutical company’s stock after purchasing an additional 2,880 shares during the period. Oddo BHF Asset Management Sas’ holdings in Alnylam Pharmaceuticals were worth $10,923,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Bull Harbor Capital LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $210,000. Rock Springs Capital Management LP boosted its holdings in Alnylam Pharmaceuticals by 3.9% in the first quarter. Rock Springs Capital Management LP now owns 74,000 shares of the biopharmaceutical company’s stock valued at $24,484,000 after purchasing an additional 2,750 shares in the last quarter. Quantinno Capital Management LP boosted its holdings in Alnylam Pharmaceuticals by 32.3% in the first quarter. Quantinno Capital Management LP now owns 33,850 shares of the biopharmaceutical company’s stock valued at $11,200,000 after purchasing an additional 8,258 shares in the last quarter. SummitTX Capital L.P. increased its stake in Alnylam Pharmaceuticals by 4.2% in the first quarter. SummitTX Capital L.P. now owns 3,611 shares of the biopharmaceutical company’s stock valued at $1,195,000 after purchasing an additional 146 shares during the last quarter. Finally, Lazard Asset Management LLC raised its holdings in Alnylam Pharmaceuticals by 60.4% during the first quarter. Lazard Asset Management LLC now owns 16,280 shares of the biopharmaceutical company’s stock worth $5,387,000 after purchasing an additional 6,128 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the subject of several recent analyst reports. Citigroup initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They set a “buy” rating and a $380.00 price objective for the company. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Bank of America reduced their price target on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Wells Fargo & Company upped their price objective on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a research note on Friday, May 1st. Finally, Morgan Stanley lifted their target price on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the stock an “equal weight” rating in a research report on Friday, July 10th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $452.13.

Alnylam Pharmaceuticals Trading Down 0.6%

Shares of ALNY stock opened at $286.62 on Thursday. The business’s 50 day moving average is $291.70 and its two-hundred day moving average is $313.42. Alnylam Pharmaceuticals, Inc. has a twelve month low of $262.21 and a twelve month high of $495.55. The company has a market capitalization of $38.27 billion, a P/E ratio of 78.31 and a beta of 0.27. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the company posted ($0.44) earnings per share. The company’s revenue for the quarter was up 96.4% compared to the same quarter last year. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.35 EPS for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.